Role of molecular imaging in the management of patients affected by inflammatory bowel disease:State-of-the-art

AIM To present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease(IBD).METHODS A systematic review of the literature was performed in order to find important original articles on the role of molecular imaging in the management of patients affected by IBD. The search was updated until February 2016 and limited to articles in English.RESULTS Fifty-five original articles were included in this review, highlighting the role of single photon emission tomography and positron emission tomography. CONCLUSION To date, molecular imaging represents a useful tool to detect active disease in IBD. However, the available data need to be validated in prospective multicenter studies on larger patient samples.

日本核医学论文摘要选登

甲状腺髓样癌复发患者^18F-DOPAPET／CT显像的预后预测价值 【摘要】目的甲状腺髓样癌（MTC）占甲状腺癌的5%～8%。血清降钙素和癌胚抗原（CEA）的测定已被广泛应用于MTC进展的监测。但临床仍希望有能够预测预后的相关检查。该研究的目的是评价18F-多巴（DOPA）PET/CT显像在MTC复发患者中的预后预测价值。方法60例MTC复发患者[年龄44～82岁，平均（64±13）岁]行18F-DOPA PET/CT显像用于再分期，显像时间在手术后至少半年。记录患者的CEA和降钙素水平，PET/CT显像所示局部复发、淋巴结受累及远处转移情况。以峰值活度的40%作为阈值对每个病灶自动设置感兴趣容积（VOI），计算代谢性肿瘤体积（MTV）、最大标准摄取值（SUVmax）、平均标准摄取值（SUVmean）；同时以纵隔放射性摄取计算标化SUVmax和SUVmean，即nSUVmax和nSUVmean 。所有患者行临床和放射影像学随访（21±11）个月。使用Kaplan-Meier生存率曲线和时序检验评价无进展生存（PFS）率、疾病特异性生存（DSS）率，分析18F-DOPA PET/CT显像较常规影像学检查的预后预测增益价值。对预后预测的相关因素采用单变量和多变量Cox回归分析法进行评价。结果18F-DOPA PET/CT显像发现27例患者有异常病灶（45%），其余33例未见明显异常（55%）。PET/CT显像未见异常的患者PFS、DSS均高于有异常病灶的患者（P＝0.018、0.04）。与常规影像学检查比较，18F-DOPA PET/CT显像对PFS和DSS的预测有增益价值（P〈0.001、P＝0.012）。半定量的PET参数和临床资料或实验室检查结果均无法预测MTC复发患者PFS和DSS的降低。结论18F-DOPA PET/CT显像在MTC复发患者疾病进展和死亡率上有预后预测价值。